AZN: Enhertu Continues To Show Meaningful Tumor Response In Lung Cancer Across Phase II Trial
(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo''s Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful tumor responses in previously-treated patients with HER2-mutant (HER2m) unresectable and|or metastatic non-squamous non-small cell lung cancer or
AZN: Enhertu Continues To Show Meaningful Tumor Response In Lung Cancer Across Phase II Trial
(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo''s Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful tumor responses in previously-treated patients with HER2-mutant (HER2m) unresectable and|or metastatic non-squamous non-small cell lung cancer or